Dermata Therapeutics, Inc. 8-K

What Happened

• Dermata Therapeutics, Inc. filed an 8-K reporting that director Mary Fisher provided notice on February 23, 2026 that she will resign from the Board of Directors and from any board committees, effective March 31, 2026.
• The filing states Ms. Fisher’s resignation is not the result of any disagreement with the company or its management; she is stepping down because her employer was recently acquired and will no longer permit her to serve on Dermata’s board. Upon her resignation the board size will be reduced from eight members to seven.

Key Details

• Notice date: February 23, 2026 (filing date: February 25, 2026).
• Effective resignation date: March 31, 2026.
• Reason given: employer acquisition that precludes board service.
• Board size change: reduced from 8 to 7 members after resignation.

Why It Matters

• Board composition and committee membership can affect corporate governance and oversight; investors should note a director departure and the temporary reduction in board size.
• The company did not report any disagreements with management, and no replacement director was named in this filing. Investors may want to watch future SEC filings or company announcements for any appointment or committee reassignments.